Mark C Petrie1, Pardeep S Jhund1, Lilin She2, Christopher Adlbrecht3, Torsten Doenst4, Julio A Panza5, James A Hill6, Kerry L Lee2, Jean L Rouleau7, David L Prior8, Imtiaz S Ali9, Jyotsna Maddury10, Krzysztof S Golba11, Harvey D White12, Peter Carson13, Lukasz Chrzanowski14, Alexander Romanov15, Alan B Miller16, Eric J Velazquez2. 1. BHF GCRC, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom. 2. Duke Clinical Research Institute and Departments of Biostatistics and Bioinformatics (KLL) and Medicine (EJV), Duke University School of Medicine, Durham, North Carolina, USA. 3. Department of Medicine II, Division of Cardiology, Medical University of Vienna and 4 Medical Department, Hietzing Hospital, Vienna, Austria. 4. Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller University of Jena, Germany. 5. Westchester Medical Center and New York Medical College, Valhalla, New York, USA. 6. University of Florida, Gainesville, USA. 7. University of Montreal, Montreal Heart Institute, Montreal, Canada. 8. Department of Cardiology, St. Vincent's Hospital, University of Melbourne, Australia. 9. Libin Cardiovascular Institute of Alberta, University of Calgary, Canada. 10. Department of Cardiology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India. 11. Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland. 12. Auckland City Hospital Greenlane Cardiovascular Services, Auckland, New Zealand. 13. Washington, DC VA Medical Center, USA. 14. Department of Cardiology, Medical University of Lodz, Poland. 15. Arrhythmia Department and Electrophysiology Laboratory, State Research Institute of Circulation Pathology, Novosibirsk, Russia. 16. Department of Cardiology, University of Florida, Jacksonville, USA.
Abstract
BACKGROUND: Advancing age is associated with a greater prevalence of coronary artery disease in heart failure with reduced ejection fraction and with a higher risk of complications after coronary artery bypass grafting (CABG). Whether the efficacy of CABG compared with medical therapy (MED) in patients with heart failure caused by ischemic cardiomyopathy is the same in patients of different ages is unknown. METHODS: A total of 1212 patients (median follow-up, 9.8 years) with ejection fraction ≤35% and coronary disease amenable to CABG were randomized to CABG or MED in the STICH trial (Surgical Treatment for Ischemic Heart Failure). RESULTS: Mean age at trial entry was 60 years; 12% were women; 36% were nonwhite; and the baseline ejection fraction was 28%. For the present analyses, patients were categorized by age quartiles: quartile 1, ≤54 years; quartile, 2 >54 and ≤60 years; quartile 3, >60 and ≤67 years; and quartile 4, >67 years. Older versus younger patients had more comorbidities. All-cause mortality was higher in older compared with younger patients assigned to MED (79% versus 60% for quartiles 4 and 1, respectively; log-rank P=0.005) and CABG (68% versus 48% for quartiles 4 and 1, respectively; log-rank P<0.001). In contrast, cardiovascular mortality was not statistically significantly different across the spectrum of age in the MED group (53% versus 49% for quartiles 4 and 1, respectively; log-rank P=0.388) or CABG group (39% versus 35% for quartiles 4 and 1, respectively; log-rank P=0.103). Cardiovascular deaths accounted for a greater proportion of deaths in the youngest versus oldest quartile (79% versus 62%). The effect of CABG versus MED on all-cause mortality tended to diminish with increasing age (Pinteraction=0.062), whereas the benefit of CABG on cardiovascular mortality was consistent over all ages (Pinteraction=0.307). There was a greater reduction in all-cause mortality or cardiovascular hospitalization with CABG versus MED in younger compared with older patients (Pinteraction=0.004). In the CABG group, cardiopulmonary bypass time or days in intensive care did not differ for older versus younger patients. CONCLUSIONS:CABG added to MED has a more substantial benefit on all-cause mortality and the combination of all-cause mortality and cardiovascular hospitalization in younger compared with older patients. CABG added to MED has a consistent beneficial effect on cardiovascular mortality regardless of age. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.
RCT Entities:
BACKGROUND: Advancing age is associated with a greater prevalence of coronary artery disease in heart failure with reduced ejection fraction and with a higher risk of complications after coronary artery bypass grafting (CABG). Whether the efficacy of CABG compared with medical therapy (MED) in patients with heart failure caused by ischemic cardiomyopathy is the same in patients of different ages is unknown. METHODS: A total of 1212 patients (median follow-up, 9.8 years) with ejection fraction ≤35% and coronary disease amenable to CABG were randomized to CABG or MED in the STICH trial (Surgical Treatment for Ischemic Heart Failure). RESULTS: Mean age at trial entry was 60 years; 12% were women; 36% were nonwhite; and the baseline ejection fraction was 28%. For the present analyses, patients were categorized by age quartiles: quartile 1, ≤54 years; quartile, 2 >54 and ≤60 years; quartile 3, >60 and ≤67 years; and quartile 4, >67 years. Older versus younger patients had more comorbidities. All-cause mortality was higher in older compared with younger patients assigned to MED (79% versus 60% for quartiles 4 and 1, respectively; log-rank P=0.005) and CABG (68% versus 48% for quartiles 4 and 1, respectively; log-rank P<0.001). In contrast, cardiovascular mortality was not statistically significantly different across the spectrum of age in the MED group (53% versus 49% for quartiles 4 and 1, respectively; log-rank P=0.388) or CABG group (39% versus 35% for quartiles 4 and 1, respectively; log-rank P=0.103). Cardiovascular deaths accounted for a greater proportion of deaths in the youngest versus oldest quartile (79% versus 62%). The effect of CABG versus MED on all-cause mortality tended to diminish with increasing age (Pinteraction=0.062), whereas the benefit of CABG on cardiovascular mortality was consistent over all ages (Pinteraction=0.307). There was a greater reduction in all-cause mortality or cardiovascular hospitalization with CABG versus MED in younger compared with older patients (Pinteraction=0.004). In the CABG group, cardiopulmonary bypass time or days in intensive care did not differ for older versus younger patients. CONCLUSIONS: CABG added to MED has a more substantial benefit on all-cause mortality and the combination of all-cause mortality and cardiovascular hospitalization in younger compared with older patients. CABG added to MED has a consistent beneficial effect on cardiovascular mortality regardless of age. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.
Authors: Stuart J Pocock; Cono A Ariti; John J V McMurray; Aldo Maggioni; Lars Køber; Iain B Squire; Karl Swedberg; Joanna Dobson; Katrina K Poppe; Gillian A Whalley; Rob N Doughty Journal: Eur Heart J Date: 2012-10-24 Impact factor: 29.983
Authors: Eric J Velazquez; Kerry L Lee; Marek A Deja; Anil Jain; George Sopko; Andrey Marchenko; Imtiaz S Ali; Gerald Pohost; Sinisa Gradinac; William T Abraham; Michael Yii; Dorairaj Prabhakaran; Hanna Szwed; Paolo Ferrazzi; Mark C Petrie; Christopher M O'Connor; Pradit Panchavinnin; Lilin She; Robert O Bonow; Gena Roush Rankin; Robert H Jones; Jean-Lucien Rouleau Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Chuntao Wu; Fabian T Camacho; Andrew S Wechsler; Stephen Lahey; Alfred T Culliford; Desmond Jordan; Jeffrey P Gold; Robert S D Higgins; Craig R Smith; Edward L Hannan Journal: Circulation Date: 2012-04-30 Impact factor: 29.690
Authors: Alain Cohen-Solal; John J V McMurray; Karl Swedberg; Marc A Pfeffer; Margareta Puu; Scott D Solomon; Eric L Michelson; Salim Yusuf; Christopher B Granger Journal: Eur Heart J Date: 2008-11-05 Impact factor: 29.983
Authors: Chih M Wong; Nathaniel M Hawkins; Mark C Petrie; Pardeep S Jhund; Roy S Gardner; Cono A Ariti; Katrina K Poppe; Nikki Earle; Gillian A Whalley; Iain B Squire; Robert N Doughty; John J V McMurray Journal: Eur Heart J Date: 2014-06-17 Impact factor: 29.983
Authors: Eric J Velazquez; Kerry L Lee; Robert H Jones; Hussein R Al-Khalidi; James A Hill; Julio A Panza; Robert E Michler; Robert O Bonow; Torsten Doenst; Mark C Petrie; Jae K Oh; Lilin She; Vanessa L Moore; Patrice Desvigne-Nickens; George Sopko; Jean L Rouleau Journal: N Engl J Med Date: 2016-04-03 Impact factor: 91.245
Authors: Pardeep S Jhund; Michael Fu; Edmundo Bayram; Chen-Huan Chen; Marta Negrusz-Kawecka; Arvo Rosenthal; Akshay S Desai; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray; Milton Packer Journal: Eur Heart J Date: 2015-07-31 Impact factor: 29.983
Authors: Andrew P Ambrosy; Susanna R Stevens; Hussein R Al-Khalidi; Jean L Rouleau; Nadia Bouabdallaoui; Peter E Carson; Christopher Adlbrecht; John G F Cleland; Rafal Dabrowski; Krzysztof S Golba; Ileana L Pina; Carla A Sueta; Ambuj Roy; George Sopko; Robert O Bonow; Eric J Velazquez Journal: Eur J Heart Fail Date: 2019-01-30 Impact factor: 15.534
Authors: Yasir Abdul Ghaffar; Waddah Maskoun; Nowwar G Mustafa; Harvey Feigenbaum; Stephen G Sawada Journal: Int J Cardiovasc Imaging Date: 2019-05-03 Impact factor: 2.357